非布索坦国内售价

In the more than 50 years since sodium urate crystals were reported in the joints of gout patients, more than 5 million cases of gout have been diagnosed in the European Union and the United States. The best method to measure the incidence and epidemiological characteristics of gout is still controversial. The prevalence of gout among adults in developed countries is 1% to 2%. The most important biochemical basis of gout is hyperuricemia. Gout is a recurring inflammatory disease caused by the deposition of urate crystals in joints, cartilage, and kidneys. In the history of gout treatment, colchicine was discovered in the 13th century, the uricosuric drug probenecid appeared in 1950, the uricosuric drug allopurinol appeared in 1960, the uricosuric drug benzbromarone appeared in 1967, and xanthine oxidase inhibitors appeared in 2004.

Febuxostat is a new non-purine xanthine oxidase (XO) selective inhibitor that works by reducing blood urate concentration. It is completely absorbed orally and has high bioavailability. Food and antacids have no significant effect on its absorption. Febuxostat is a selective inhibitor of non-purine xanthine oxidase/xanthine dehydrogenase. It works by reducing blood urate concentration. Unlike allopurinol, its structure is a non-purine analogue, so it is selective for the inhibition of xanthine oxidase and other enzymes in purine or pyrimidine metabolism (such as guanine). Deaminase, pyrimidine nucleoside phosphorylase, purine nucleoside phosphorylase, etc.) have very little effect, and allopurinol is a purine analogue, which can affect the activity of other enzymes in purine and pyrimidine metabolism in the body, and is prone to some adverse reactions. The specificity of febuxostat's inhibitory effect can avoid these possible adverse reactions, and it is clinically used to reduce blood uric acid in patients with gout.

In April 2008, the European EMEA approved the marketing of Febuxostat tablets. In February 2009, the US FDA approved the marketing of Febuxostat tablets. It was the first new anti-gout drug approved by the FDA in the past 40 years. On June 26, 2013, the China State Food and Drug Administration issued a new drug certificate for Febuxostat tablets to Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. The approved ones are 40mg×16 tablets/box and 80mg×6 tablets/box. Compared with similar drugs, febuxostat has high selectivity and stronger activity. Its efficacy is better than that of allopurinol, the current gold standard treatment for gout, and its efficacy is rapid and its adverse reactions are mild. As a new anti-uric acid drug, febuxostat has ended the history of allopurinol being the only drug in the world, created a new era of gout treatment, and provided new treatment options for gout patients.

The price of febuxostat on the domestic market is 10$ per tablet, 40mg/tablet, and the recommended dosage is 40mg/day, which means it costs about 300$ a month. Patients with poor absorption of febuxostat may need to increase the dosage to 80mg/day, which means they need two tablets a day, which costs about 600$ a month. For gout patients, it is a long-term consumption.